Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Business News, In Brief

Executive Summary

Cephalon's Buchi steps in for Baldino: Cephalon CEO Frank Baldino is taking a temporary medical leave of absence, and the company's long-time financial head Kevin Buchi will take over his responsibilities in the meantime, the firm announced Aug. 25. Buchi, having worked with Baldino for decades, is well-groomed to step in. He joined Cephalon in 1991 as controller and was appointed CFO in 1996. He was promoted to Chief Operating Officer earlier this year. Baldino is due to return to the company before the end of the year. If his absence is indeed only a few months long, the disruption should not have a material impact on the company, given Cephalon's experienced leadership team. A longer-term absence, however, could raise some investor alarms, because Baldino, who founded Cephalon in 1987, is the face of the company and has been steering the ship from the get-go

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052552

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel